Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders

作者：Garg Rajesh; Adler Gail K^*

来源：Current Hypertension Reports, 2015, 17(7): 52.

DOI：10.1007/s11906-015-0567-8

• Aldosterone
• Mineralocorticoid receptor
• Obesity
• Diabetes
• Metabolic syndrome
• Cardiometabolic risk
• Cardiovascular disease

Preclinical studies have convincingly demonstrated a role for the mineralocorticoid receptor (MR) in adipose tissue physiology. These studies show that increased MR activation causes adipocyte dysfunction leading to decreased production of insulin-sensitizing products and increased production of inflammatory factors, creating an environment conducive to metabolic and cardiovascular disease. Accumulating data also suggest that MR activation may be an important link between obesity and metabolic syndrome. Moreover, MR activation may mediate the pathogenic consequences of metabolic syndrome. Recent attempts at reversing cardiometabolic damage in patients with type 2 diabetes using MR antagonists have shown promising results. MR antagonists are already used to treat heart failure where their use decreases mortality and morbidity over and above the use of traditional therapies alone. However, more data are needed to establish the benefits of MR antagonists in diabetes, obesity, and metabolic syndrome.

• 出版日期2015-7